Compare VTMX & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTMX | SYRE |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2023 | 2015 |
| Metric | VTMX | SYRE |
|---|---|---|
| Price | $35.96 | $44.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $30.50 | ★ $55.57 |
| AVG Volume (30 Days) | 61.5K | ★ 623.4K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.14 | N/A |
| Revenue Next Year | $9.70 | N/A |
| P/E Ratio | $47.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.30 | $10.91 |
| 52 Week High | $36.26 | $45.76 |
| Indicator | VTMX | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 75.64 | 77.65 |
| Support Level | $30.07 | $14.62 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.90 | 2.44 |
| MACD | 0.35 | 1.07 |
| Stochastic Oscillator | 95.12 | 88.41 |
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.